AbCellera Biologics›AbCellera Biologics› offers Antibody Discovery Platform

The platform integrates biology, computation, and engineering from target selection through discovery, preclinical development, manufacturing, and clinical studies. Capabilities include proprietary single-cell screening of hundreds of antibodies, complex transmembrane protein programs for GPCRs and ion channels, T-cell engagers, bispecifics, and antibody-drug conjugates, supported by a 130,000 square foot clinical manufacturing facility in Vancouver for GMP cell banking and drug substance.

AbCellera reports more than 100 antibody drug programs with more than 40 partners since 2015, including COVID-19 antibodies with Eli Lilly through the DARPA pandemic-response platform. The company is actively partnering its T-cell engager platform for oncology and immunology applications.